BioNap trying to help, Update On BriaCell Therapeutics Following Meeting With CEO, again, see two previous articles linked.
"However, one thing I did find very interesting is that the companion diagnostic is further along in development than I suspected."
but actually, I don't see that:
"They are now going back and looking at the specific biomarkers in the responder vs. non-responder population using cutting-edge technologies including gene expression analysis and proteomics. I do not think we will see the incorporation of BriaDx in the currently planned Phase 2 trial, but the company will surely do a retrospective analysis of the data using the screening tools they are developing in-house right now."
I mean, no hints as to actual progress, let alone usefulness, here?
Bio-markers is certainly getting some attention, the immunotherapy co (SCLP in UK, with SCNLF OTC in US, I've mentioned before, but which has failed to provide the early exit they promised) has recently claimed to have some success when analysing (mainly historic) blood samples: "ImmunID's ImmunTraCkeR® assay was used to assess T cell diversity in the blood from patients before and during treatment with SCIB1. Results showed variations in T cell diversity kinetics during SCIB1 treatment, underlining the immune-modulatory effect of the vaccine, and indicated that patients had developed an immunological response to SCIB1."
The hope is that this will both help pre-select promising patients and be a bit of a surrogate end-point for future trials (thus giving earlier results), and will also tell patients whether they are responding, so whether continuing treatment is likely to help (although as SCIB1 is apparently non-toxic that isn't such a great benefit as it might be).
If BriaCell could see some biomarker/outcome correlation then maybe the wait until "we should see data roughly 15-18 months later - so likely during the second half of 2017. " might be shortened.
Maybe BCT is just too far from results to be of sufficient interest at present. |
